{4-[2-(2-[6-aminopyridin-3-yl]-2-(R)-hydroxyethylamino)ethoxy]phenyl}acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: {4-[2-(2-[6-aminopyridin-3-yl]-2-(R)-hydroxyethylamino)ethoxy]phenyl}acetic acid
• 英文别名: (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid；(R)-(4-(2-(2-(6-aminopyridin-3-yl)-2-hydroxyethylamino)ethoxy)phenyl)acetic acid；(4-{2-[2-(6-aminopyridin-3-yl)-(2R)-hydroxyethylamino]ethoxy}phenyl)acetic acid；{4-[2-(2-[6-aminopyridin-3-y]-2(R)-hydroxyethylamino)ethoxy]phenyl}acetic acid；{4-[2-(2-[6-aminopyridin-3-yl]-2(R)-hydroxyethylamino)ethoxy]phenyl} acetic acid；{4-[2-(2-[6-aminopyridin-3-yl]-2(R)-hydroxyethylamino)ethoxy]phenyl}acetic acid；2-[4-[2-[[(2R)-2-(6-aminopyridin-3-yl)-2-hydroxyethyl]azaniumyl]ethoxy]phenyl]acetate
• 化学式: C₁₇H₂₁N₃O₄
• 分子量: 331.371
• InChiKey: GZJZZQHTBTUBEL-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  甲醇 、 {4-[2-(2-[6-aminopyridin-3-yl]-2-(R)-hydroxyethylamino)ethoxy]phenyl}acetic acid 在 氯化亚砜 作用下， 生成 methyl (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)-ethoxy)phenyl)acetate
  参考文献：
  名称：

  β-3 肾上腺素能受体激动剂的工艺研究和放大

  摘要：

  介绍了 β-3 肾上腺素能受体激动剂 (4-{2-[2-(6-aminopyridin-3-yl)-(2R)-羟基-乙基氨基]乙氧基}苯基)乙酸的可规模合成。关键的偶联步骤利用甲硅烷基-p ...

  DOI：

  10.1021/op049969o
• 作为产物：
  描述：

  methyl (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)-ethoxy)phenyl)acetate 在 盐酸 、 水 作用下， 生成 {4-[2-(2-[6-aminopyridin-3-yl]-2-(R)-hydroxyethylamino)ethoxy]phenyl}acetic acid
  参考文献：
  名称：

  β-3 肾上腺素能受体激动剂的工艺研究和放大

  摘要：

  介绍了 β-3 肾上腺素能受体激动剂 (4-{2-[2-(6-aminopyridin-3-yl)-(2R)-羟基-乙基氨基]乙氧基}苯基)乙酸的可规模合成。关键的偶联步骤利用甲硅烷基-p ...

  DOI：

  10.1021/op049969o

文献信息

• Compounds for the treatment of obesity
  申请人：——

  公开号：US20010039277A1

  公开（公告）日：2001-11-08

  NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.

  NPY拮抗剂，使用此类NPY拮抗剂的方法以及含有此类NPY拮抗剂的药物组合物。这些NPY拮抗剂对于治疗由NPY介导的疾病/症状，包括肥胖症，是有用的。
• Triamide-substituted heterobicyclic compounds
  申请人：Pfizer Inc.

  公开号：US20030187053A1

  公开（公告）日：2003-10-02

  The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1 wherein R 1 -R 8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

  本发明涉及三酰胺MTP/ApoB抑制剂，其化学公式为1，其中R1-R8如说明书所述，以及包含这些化合物的药物组合物及其用途，以及制备这些化合物的方法。本发明的化合物可用于治疗肥胖和脂质紊乱。
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• [EN] FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS HÉTÉROARYLE CONDENSÉS, DE L'ACTIVITÉ AP-1 ET/OU NF-?B DU RÉCEPTEUR DES GLUCOCORTICOÏDES ET LEUR UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009100171A1

  公开（公告）日：2009-08-13

  Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or taυtomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; • A is a S- to 8- membered carbocyclic ring or a S- to 8-membered heterocyclic ring; B1 and B2 rings are pyridyl rings, wherein the B1 and B2 rings are each fused to the A ring and the B1 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R1, R2, and R4, and the B2 ring is optionally substituted by one to three groups which are the same or different and are independently selected from R5, R7, and R3 J1, J2, and J3 are at each occurrence the same or different and are independently - A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3 alkylene, substituted C1-3 alkylene, C2-4 alkenylene, and substituted C2-4 alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein....

  提供了一种新型的非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病或紊乱，包括代谢性、炎症性和免疫性疾病或紊乱，其结构如下式（I）：其对映体、非对映体或互变异构体，或其前药酯，或其药用可接受盐，其中：Z是杂环或杂芳基；• A是S至8-成员碳环或S至8-成员杂环；B1和B2环是吡啶环，其中B1和B2环各与A环融合，B1环可选地由一个至三个基取代，所述基相同或不同，并且独立地从R1、R2和R4中选择，B2环可选地由一个至三个基取代，所述基相同或不同，并且独立地从R5、R7和R3中选择，J1、J2和J3在每次出现时相同或不同，并且独立地为-A1QA2-；Q是键，O，S，S（O）或S（O）2；A1和A2相同或不同，并且在每次出现时独立地从键，C1-3烷基，取代C1-3烷基，C2-4烯烃基和取代C2-4烯烃基中选择，前提是选择A1和A2以使环A为5-至8-成员碳环或杂环；R1至R11如此处所定义...